Eli Lilly Reports Strong Weight Loss Results for Retatrutide in Late-Stage Obesity Trial

Eli Lilly (NYSE: LLY) said its experimental obesity drug retatrutide produced significant weight loss in a late-stage trial, adding to the company’s pipeline of treatments for obesity and diabetes.

Patients who received the highest dose lost an average of 28.3% of their body weight, or 70.3 pounds, over 80 weeks. The result was measured among patients who remained on treatment during the trial.

The study included roughly 2,500 patients. Lilly said about 45% of participants in the Phase 3 trial lost at least 30% of their body weight.

Retatrutide is a weekly injection that targets GLP-1, GIP and glucagon. That separates it from Lilly’s Zepbound, which uses tirzepatide to mimic GLP-1 and GIP, and Novo Nordisk’s Wegovy, which uses semaglutide to mimic GLP-1.

The drug has been described as a “triple G” treatment because of its 3-hormone mechanism. According to the provided material, the approach appears to have stronger effects on appetite and satisfaction with food than existing treatments.

The results come as Lilly maintains a leading share of the U.S. obesity and diabetes drug market. The company held a 60.1% share in the first quarter, according to an earnings presentation, compared with Novo Nordisk’s 39.4%.

Novo has also been working to expand its weight-loss pipeline. In March 2025, the company agreed to pay up to $2 billion for rights to an early experimental drug from China’s United Laboratories International. That treatment also uses a 3-pronged approach to weight loss and blood sugar control, though it remains earlier in development than retatrutide.

The trial moves Lilly closer to filing for approval of retatrutide. The company did not specify a filing date in the provided material.

About Eli Lilly

Eli Lilly and Company (NYSE: LLY) is a pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company develops and markets medicines across areas including diabetes, obesity, oncology, immunology and neuroscience.

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.